|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-12-27
|
|
pubmed:abstractText |
Allogeneic hematopoietic stem cell transplantation (SCT) regimens incorporating the lymphocytotoxic CD52 antibody alemtuzumab demonstrate efficient engraftment and reduced graft-versus-host disease (GVHD). However, these protocols substantially impair posttransplantation antiviral and antitumor immunity. To accelerate immune reconstitution after alemtuzumab-based reduced-intensity SCT, we administered prophylactic CD8-depleted donor lymphocyte infusions (DLIs) starting on days 60 and 120 after transplantation. DLIs were processed in an immunomagnetic good manufacturing practice depletion procedure resulting in a 2.5- to 6-log reduction in CD8 T cells. Of 23 high-risk patients with hematologic malignancies, 11 received a total of 21 CD8-depleted DLIs. Five patients developed transient grade I acute GVHD following transfer. Only 2 patients with HLA-C-mismatched donors showed grade II and III acute GVHD and subsequently progressed to limited chronic GVHD. Following DLIs, 4 patients with declining hematopoietic donor chimerism converted to full chimeras. A 2.1-fold median increase of circulating CD4 T cells was observed within 2 weeks after infusion. Non-DLI patients did not show a comparable rise in CD4 counts. Four patients demonstrated enhanced frequencies of cytomegalovirus-specific CD4 and CD8 T cells following transfer. Our results suggest that prophylactic CD8-depleted DLIs accelerate immune reconstitution after lymphodepleted HLA-matched SCT and carry a low risk of inducing severe GVHD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
pubmed-author:BenderKlausK,
pubmed-author:BrittenCedrik MCM,
pubmed-author:GentiliniChiaraC,
pubmed-author:HartwigUdo FUF,
pubmed-author:HerrWolfgangW,
pubmed-author:HessGeorgG,
pubmed-author:HuberChristophC,
pubmed-author:KolbeKarinK,
pubmed-author:KonurAbdoA,
pubmed-author:MeyerRalf GRG,
pubmed-author:UharekLutzL,
pubmed-author:UllmannAndrew JAJ,
pubmed-author:WehlerDanielaD,
pubmed-author:WehlerThomas CTC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
109
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
374-82
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16940425-Adult,
pubmed-meshheading:16940425-Antibodies, Monoclonal,
pubmed-meshheading:16940425-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16940425-Antibodies, Neoplasm,
pubmed-meshheading:16940425-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16940425-Female,
pubmed-meshheading:16940425-Follow-Up Studies,
pubmed-meshheading:16940425-Graft Survival,
pubmed-meshheading:16940425-Graft vs Host Disease,
pubmed-meshheading:16940425-HLA Antigens,
pubmed-meshheading:16940425-Hematologic Neoplasms,
pubmed-meshheading:16940425-Humans,
pubmed-meshheading:16940425-Immunomagnetic Separation,
pubmed-meshheading:16940425-Immunotherapy, Adoptive,
pubmed-meshheading:16940425-K562 Cells,
pubmed-meshheading:16940425-Langerhans Cells,
pubmed-meshheading:16940425-Lymphocyte Depletion,
pubmed-meshheading:16940425-Male,
pubmed-meshheading:16940425-Middle Aged,
pubmed-meshheading:16940425-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:16940425-Transplantation Conditioning,
pubmed-meshheading:16940425-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation.
|
|
pubmed:affiliation |
Department of Medicine III, Hematology and Oncology, Johannes Gutenberg-University, Mainz, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
